Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus.
This trial evaluated the effects of 16 weeks of consumption of 1000mg rebaudioside A (n=60) a steviol glycoside with potential use as a sweetener, compared to placebo (n=62) in men and women (33-75 years of age) with type 2 diabetes mellitus. Mean+/-standard error changes in glycosylated hemoglobin levels did not differ significantly between the rebaudioside A (0.11+/-0.06%) and placebo (0.09+/-0.05%; p=0.355) groups. Changes from baseline for rebaudioside A and placebo, respectively, in fasting glucose (7.5+/-3.7mg/dL and 11.2+/-4.5mg/dL), insulin (1.0+/-0.64microU/mL and 3.3+/-1.5microU/mL), and C-peptide (0.13+/-0.09ng/mL and 0.42+/-0.14ng/mL) did not differ significantly (p>0.05 for all). Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment. Rebaudioside A was well-tolerated, and records of hypoglycemic episodes showed no excess vs. placebo. These results suggest that chronic use of 1000mg rebaudioside A does not alter glucose homeostasis or blood pressure in individuals with type 2 diabetes mellitus.
Maki
K C
KC
Provident Clinical Research, 1000 West 1st Street, Bloomington, IN, United States.
Curry
L L
LL
Reeves
M S
MS
Toth
P D
PD
McKenney
J M
JM
Farmer
M V
MV
Schwartz
S L
SL
Lubin
B C
BC
Boileau
A C
AC
Dicklin
M R
MR
Carakostas
M C
MC
Tarka
S M
SM
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D045786:Diterpenes, Kaurane / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005215:Fasting; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007003:Hypoglycemia / Q000453:epidemiology; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013549:Sweetening Agents / Q000008:administration & dosage* / Q000009:adverse effects
D001786:Blood Glucose; D002096:C-Peptide; D045786:Diterpenes, Kaurane; D006442:Glycated Hemoglobin; D008055:Lipids; D010919:Placebos; D013549:Sweetening Agents; C025474:rebaudioside A